Patents Assigned to Southern Research Institute
  • Patent number: 10379333
    Abstract: An apparatus for imaging a feature within a specimen is provided. According to one implementation the apparatus includes a substrate that is configured to support a specimen on an upper surface of the substrate so that the specimen resides over a hole that extends through the substrate. A heater is located vertically above the upper surface of the substrate. The heater is configured to heat the specimen when the specimen is supported on the substrate. An imaging device is located vertically below the lower surface of the substrate. The imaging device has an unobstructed line of sight to and through the hole in the substrate. The lower surface of the substrate is supported on a heat insulating platform in a manner that permits air to flow between the heat insulating platform and the lower surface of the substrate.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: August 13, 2019
    Assignee: Southern Research Institute
    Inventors: William Carter Ralph, Kevin Connolly
  • Patent number: 10343148
    Abstract: A catalyst structure includes a plurality of metal oxides formed on a support, where the support includes zirconia and/or silica. The metal oxides include at least three metals selected from the group consisting of chromium, iron, nickel, and a platinum group metal. The catalyst structure can be used in an oxidative dehydrogenation (ODH) reaction process for converting an alkane to an olefin. In some embodiments, carbon dioxide utilized in the ODH reaction process is obtained from a flue gas derived from a fossil fuel burning power plant.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: July 9, 2019
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Amit Goyal, Jadid Samad
  • Patent number: 10294235
    Abstract: The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (LRRK2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal LRRK2 kinase activity. Compounds of the present disclosure can be used to treat disorders including neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy (Hansen's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: May 21, 2019
    Assignee: Southern Research Institute
    Inventors: Corinne E. Augelli-Szafran, Mark Suto, Robert Galemmo, Omar Moukha-Chafiq, Vandana Gupta, Subramaniam Ananthan
  • Patent number: 10266823
    Abstract: Methods of administering an oligonucleotide of interest into a cell in vitro or in vivo are described. In the methods, a small organic compound active agent is concurrently administered to the cell in an amount effective to increase the delivery of the oligonucleotide into the cell, and/or increase the activity of said oligonucleotide in the cell. Compositions useful for carrying out the method are also described.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: April 23, 2019
    Assignees: The University of North Carolina at Chapel Hill, Southern Research Institute
    Inventors: Rudolph Juliano, William P. Janzen, Joseph A. Maddry, Canhong Cao, Xin Ming, Bing Yang
  • Patent number: 10144000
    Abstract: Nickel based catalyst structures are described herein that include a plurality of metal oxides formed as crystalline phases within the catalyst structures. Each metal oxide of a catalyst structure includes nickel and/or aluminum, where one or more metal oxides includes a nickel aluminum oxide, and the one or more nickel aluminum oxides is greater than 50% by weight of the catalyst structure. The catalyst structures further have surface areas of at least 13 m2/g. The catalyst structures are resistant to high concentrations of sulfur and are effective in reforming operations for converting methane and other light hydrocarbons to hydrogen and one or more other components. For example, the catalyst structures are effective in coal and biomass gasification systems for the forming and cleanup of synthetic gas.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: December 4, 2018
    Assignee: Southern Research Institute
    Inventors: Amit Goyal, Santosh Gangwal, Andrew Lucero
  • Patent number: 10126120
    Abstract: An apparatus for measuring the angular position of a rotatable body comprises: refractive elements extending radially outward from a peripheral surface of the rotatable body at respective angular locations; first and second emitters that respectively emit first and second light beams along first and second path extending through respectively first and second regions within an annual vicinity around the rotatable body, wherein the refractive elements are arranged to pass through and laterally shift the light beams upon rotation of the rotatable body; first and second detectors arranged to respectively receive the first and second light beams and to determine respective first and second lateral offsets of the light beams caused by the time-varying angular orientation of refractive elements within the light beams; and a processor that determines an angular position of the rotatable body based on the first and second lateral offsets.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: November 13, 2018
    Assignee: Southern Research Institute
    Inventor: James Richard Tucker
  • Patent number: 10087148
    Abstract: The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 2, 2018
    Assignees: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTE OF HEALTH, SOUTHERN RESEARCH INSTITUTE
    Inventors: Subramaniam Ananthan, Richard B. Rothman
  • Patent number: 10087168
    Abstract: The present technology relates to compounds and compositions of Formulas I-III and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: October 2, 2018
    Assignees: UNIVERSITY OF KANSAS, UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., SOUTHERN RESEARCH INSTITUTE
    Inventors: Jennifer Golden, Jeffrey Aube, Donghoon Chung, Chad Schroeder, Tuanli Yao, E. Lucile White, Nichole A. Tower
  • Patent number: 10080784
    Abstract: The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.
    Type: Grant
    Filed: February 20, 2012
    Date of Patent: September 25, 2018
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: William B. Parker, Eric J. Sorscher
  • Patent number: 10041781
    Abstract: An interferometer is provided that includes a single retroreflector arranged at a target plane and a plurality of retroreflectors arranged at a reference plane of the interferometer. The single retroreflector and the plurality of retroreflectors are positioned such that a measurement beam provided to the interferometer makes a plurality of passes between the single retroreflector and the plurality of retroreflectors. One of the plurality of retroreflectors is positioned as a terminal retroreflector that reflects the measurement beam back on itself such that an output of the interferometer is coaxial with an input to the interferometer.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: August 7, 2018
    Assignee: Southern Research Institute
    Inventor: James Richard Tucker
  • Patent number: 10038131
    Abstract: Disclosed herein is a method and apparatus that uses a brine from a well that is used to both generate electricity and recover valuable minerals present in the brine. The method and apparatus uses a hydrophobic membrane to separate water vapor from the brine to concentrate the brine that is then used to recover the minerals.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: July 31, 2018
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Ryan Melsert, Jay Renew
  • Patent number: 10023579
    Abstract: The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (LRRK2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal LRRK2 kinase activity. Compounds of the present disclosure can be used to treat disorders including neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy (Hansen's disease). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: July 17, 2018
    Assignee: Southern Research Institute
    Inventors: Corinne E. Augelli-Szafran, Mark Suto, Robert Galemmo, Omar Moukha-Chafiq, Vandana Gupta, Subramaniam Ananthan
  • Publication number: 20180154341
    Abstract: A catalyst structure includes a plurality of metal oxides formed on a support, where the support includes zirconia and/or silica. The metal oxides include at least three metals selected from the group consisting of chromium, iron, nickel, and a platinum group metal. The catalyst structure can be used in an oxidative dehydrogenation (ODH) reaction process for converting an alkane to an olefin. In some embodiments, carbon dioxide utilized in the ODH reaction process is obtained from a flue gas derived from a fossil fuel burning power plant.
    Type: Application
    Filed: December 1, 2016
    Publication date: June 7, 2018
    Applicant: Southern Research Institute
    Inventors: Amit GOYAL, Jadid SAMAD
  • Patent number: 9980969
    Abstract: The invention provides methods of enhancing memory and/or learning and prevent neurodegeneration, comprising administering therapeutically effective amounts of certain heterocyclic and aromatic compounds to a patient in need thereof. In one aspect, the invention provides methods of treating patients suffering from a neurodegenerative disease, such as but not limited to, Alzheimer's, Parkinsons's, Lou Gehrig's (ALS) disease, and/or memory or learning impairment. The invention further provides neuronal human cell-based assays that assess NF-kB gene upregulation using a luciferase reporter, wherein the assays identify compounds that are useful in enhancing memory or learning.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: May 29, 2018
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Maurizio Grimaldi, Judith Varady Hobrath, Subramaniam Ananthan, Joseph A. Maddry
  • Patent number: 9969743
    Abstract: Provided are compounds represented by the formula: In which: Y is an unbranched, saturated or unsaturated hydrocarbon chain with 2-5 hydrocarbon atoms R1=aryl R2=NR3R4 wherein R3 and R4 together form a heterocycle or R2=4-substitutedcyclohexyl, 1-substitutedpiperidine-4-yl or imidazo(1,2-a)azine-2-yl when Y is as defined above and R1 is a heterocycle other than benzothiophene pharmaceutically acceptable salts thereof, deuterated forms thereof, isomers thereof, solvates thereof, and mixtures thereof. The compounds can be used for treating a patient suffering from a condition that is capable of treatment with a partial agonist or antagonist of the dopamine D2/D3 receptors.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: May 15, 2018
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventor: Subramaniam Ananthan
  • Patent number: 9873702
    Abstract: The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 23, 2018
    Assignees: Southern Research Institute, The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Subramaniam Ananthan, Richard B. Rothman
  • Patent number: 9808264
    Abstract: In one embodiment, a hinged microfracture awl includes a handle, and a shaft that extends through and from the handle, the shaft being pivotally mounted to the handle with a hinge, wherein a distal end of the shaft includes a sharp tip adapted to pierce bone and a proximal end of the shaft includes an impact head adapted to be struck by a striking tool.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: November 7, 2017
    Assignees: THE UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTE
    Inventors: Reed Estes, Patrick Schexnailder, Robert Hergenrother
  • Patent number: 9757380
    Abstract: Methods for treating neoplasia with a chemotherapeutic agent and radiation are provided. Radiation therapies used in conduction with a compound described herein presents a synergistic effect in the treatment of cancers. A compound of formula (I): wherein X, Y, Z, R1 and R2 are defined herein, sensitize cells making them more susceptible to radiation therapy.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: September 12, 2017
    Assignee: Southern Research Institute
    Inventor: Bo Xu
  • Patent number: 9708249
    Abstract: Disclosed herein are a catalyst and method useful in the process of converting sugars to acrylonitrile.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: July 18, 2017
    Assignee: Southern Research Institute
    Inventors: Amit Goyal, Jadid Samad
  • Patent number: 9688653
    Abstract: This invention relates generally to the discovery of a method of inhibiting, preventing or treating bacterial infections. The invention also relates to a method of inhibiting bacterial capsule biogenesis.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: June 27, 2017
    Assignees: Duke University, University of Kansas, Southern Research Institute
    Inventors: Patrick C. Seed, Carlos C. Goller, Steven Rogers, Brooks Maki, Frank Schoenen, James Noah, E. Lucile White